EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter

Maneka Sheffield iD, Emma Phelan iD, Natalie Ratajczak, Marisa Battistella iD, Karthik Tennankore iD, Ayodele Odutayo iD, Steven Soroka iD, Penelope Poyah iD, Keigan More iD, Heather Naylor iD, Natalie Kennie-Kaulbach iD, Daniel Rainkie iD und 1 weitere

Canadian Journal of Kidney Health and Disease · 2026-08 · 13

DOI: 10.1177/20543581261476643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Kidney Health and Disease, online erschienen am 13.08.2026. Verfasst von Maneka Sheffield und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, Canada. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dalhousie Pharmacy Endowment Fund, Dalhousie University Faculty of Health Shoppers Drug Mart Stream B.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes is a leading cause of chronic kidney disease, yet gaps in the use of guideline-directed therapies persist in primary care. In 2025, our group developed and validated community pharmacist-led prescribing algorithms for individuals with an estimated glomerular filtration rate ≥30 mL/min/1.73 m 2 , targeting angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, sodium-glucose cotransporter-2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists. To address the evolving therapeutic landscape, we developed and validated a semaglutide-specific algorithm to complement this approach. Algorithm development and validation followed Lynn’s method. A two-part questionnaire per algorithm item assessed content and face validity, with nephrology clinicians (nephrologists and kidney pharmacists) and community pharmacists rating items using Likert scales. Content validity was measured using item-level (I-CVI) and scale-level (S-CVI/Ave) indices, while face validity was assessed by level of agreement to five statements per round. The algorithm was iteratively revised between rounds. Ten nephrology clinicians (five per round for three rounds) and 12 community pharmacists (six per round for two rounds) participated. For clinicians, the I-CVI ranged from 0.6 to 1.0, with an overall S-CVI/Ave of 0.89 across three rounds. Among pharmacists, all items met the prespecified content validity threshold for both rounds (I-CVI ≥0.83; P < 0.05). Face validity exceeded the 70% consensus threshold for both validator groups. This study adds a validated semaglutide-specific algorithm to our existing pharmacist-led care model, expanding a suite of algorithms to support uptake of disease-modifying therapies for individuals with type 2 diabetes and chronic kidney disease in primary care. Implementation and evaluation in Nova Scotia community pharmacy clinics are underway.

Schlagwörter

Stichwörter der Autor:innen

algorithm validationdiabetic kidney diseaseguideline-directed prescribingpharmacistprimary caresemaglutide

Autor:innen und Institutionen

  • Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, Canada.
  • Kidney Research Institute of Nova Scotia, Nephrology, Nova Scotia Health, Halifax, NS, Canada.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
  • Department of Nephrology, Toronto General Hospital, Toronto, ON, Canada.
  • Department of Pharmacy, University Health Network, Toronto, ON, Canada.
  • Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.

ORCID-Profile: Maneka Sheffield, Emma Phelan, Marisa Battistella, Karthik Tennankore, Ayodele Odutayo, Steven Soroka, Penelope Poyah, Keigan More, Heather Naylor, Natalie Kennie-Kaulbach, Daniel Rainkie, Jo-Anne Wilson

Förderung

  • Dalhousie Pharmacy Endowment Fund
  • Dalhousie University Faculty of Health Shoppers Drug Mart Stream B

Zitieren

APA

Sheffield, M., Phelan, E., Ratajczak, N., Battistella, M., Tennankore, K., Odutayo, A., Soroka, S., Poyah, P., More, K., Naylor, H., Kennie-Kaulbach, N., Rainkie, D., & Wilson, J. A. (2026). Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter. Canadian Journal of Kidney Health and Disease, 13. https://doi.org/10.1177/20543581261476643

Vancouver

Sheffield M, Phelan E, Ratajczak N, Battistella M, Tennankore K, Odutayo A, et al. Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter. Canadian Journal of Kidney Health and Disease. 2026;13. doi:10.1177/20543581261476643

BibTeX
@article{Sheffield2026,
  author = {Sheffield, Maneka and Phelan, Emma and Ratajczak, Natalie and Battistella, Marisa and Tennankore, Karthik and Odutayo, Ayodele and Soroka, Steven and Poyah, Penelope and More, Keigan and Naylor, Heather and Kennie-Kaulbach, Natalie and Rainkie, Daniel and Wilson, Jo-Anne},
  title = {Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter},
  journal = {Canadian Journal of Kidney Health and Disease},
  year = {2026},
  volume = {13},
  doi = {10.1177/20543581261476643}
}
Kostenlos starten →